Tenofovir and its potential in the treatment of hepatitis B virus

Laura Reynaud, Maria Aurora Carleo, Maria Talamo, Guglielmo BorgiaDepartment of Public Medicine and Social Security – Section of Infectious Disease University of Naples “Federico II”, ItalyAbstract: Recent literature is reviewed about treatment of chronic hepatitis B vi...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Reynaud (Author), Maria Aurora Carleo (Author), Maria Talamo (Author), Guglielmo Borgia (Author)
Format: Book
Published: Dove Medical Press, 2009-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b757ad34c43e4a3f8c48bf5db3380be5
042 |a dc 
100 1 0 |a Laura Reynaud  |e author 
700 1 0 |a Maria Aurora Carleo  |e author 
700 1 0 |a Maria Talamo  |e author 
700 1 0 |a Guglielmo Borgia  |e author 
245 0 0 |a Tenofovir and its potential in the treatment of hepatitis B virus 
260 |b Dove Medical Press,   |c 2009-02-01T00:00:00Z. 
500 |a 1176-6336 
500 |a 1178-203X 
520 |a Laura Reynaud, Maria Aurora Carleo, Maria Talamo, Guglielmo BorgiaDepartment of Public Medicine and Social Security – Section of Infectious Disease University of Naples “Federico II”, ItalyAbstract: Recent literature is reviewed about treatment of chronic hepatitis B virus (CHB), focusing on tenofovir disoproxil fumarate (TDF; Viread®), among the nucleotide and nucleoside analogs. TDF pharmacokinetics and pharmacodynamics, activity in respect of hepatitis B virus (HBV) multi-drug-resistant mutations, efficacy in treatment-naïve and treatment-experienced patients, and side effects are described. The most predictive response factors to TDF therapy are discussed and all available combination therapies to optimize clinical outcome in the various patient profiles are analyzed, such as compensated and/or decompensated cirrhotic patients. The use of TDF in pregnancy, and prophylaxis after exposure to HBV and post-liver transplantation are also evaluated.Keywords: HBV, chronic hepatitis B, tenofovir, antiviral therapy 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Therapeutics and Clinical Risk Management, Vol 2009, Iss default, Pp 177-185 (2009) 
787 0 |n http://www.dovepress.com/tenofovir-and-its-potential-in-the-treatment-of-hepatitis-b-virus-a2834 
787 0 |n https://doaj.org/toc/1176-6336 
787 0 |n https://doaj.org/toc/1178-203X 
856 4 1 |u https://doaj.org/article/b757ad34c43e4a3f8c48bf5db3380be5  |z Connect to this object online.